Desloratadine


Generic Medicine Info
Indications and Dosage
Oral
Allergic rhinitis, Urticaria
Adult: 5 mg once daily. Patients with intermittent allergic rhinitis must be managed according to the evaluation of disease history, treatment may be discontinued after the symptoms are resolved and reinitiated upon reappearance; in case of persistent allergic rhinitis, continuous treatment may be considered during the periods of allergen exposure. Treatment recommendations may vary among countries and individual products (refer to specific product guidelines).
Child: 1-5 years As oral solution or syrup: 1.25 mg once daily; 6-11 years As orodispersible tab, oral solution or syrup: 2.5 mg once daily; ≥12 years Same as adult dose. Treatment or dosage recommendations may vary among countries and individual products (refer to specific product guidelines).
Renal Impairment
Initially, 5 mg every other day. Dosage recommendations may vary among countries and individual products (refer to specific product guidelines).
Hepatic Impairment
Initially, 5 mg every other day. Dosage recommendations may vary among countries and individual products (refer to specific product guidelines).
Administration
May be taken with or without food.
Special Precautions
Patients with medical or familial history of seizure disorders. Patients who are slow or poor metabolisers of desloratadine may have an increased risk of adverse effects. Renal and hepatic impairment. Children. Pregnancy and lactation.
Adverse Reactions
Significant: Increased risk of seizures (particularly in children). Very rarely, hypersensitivity reactions (e.g. anaphylaxis).
Gastrointestinal disorders: Dry mouth; diarrhoea (mainly in children <2 years).
General disorders and administration site conditions: Fatigue; fever (mainly in children <2 years).
Nervous system disorders: Headache.
Psychiatric disorders: Insomnia (mainly in children <2 years).
Respiratory, thoracic and mediastinal disorders: Pharyngitis; upper respiratory tract infection, cough (mainly in children <2 years).
Monitoring Parameters
Obtain renal function test and LFT at baseline. Monitor for signs and symptoms of hypersensitivity reactions.
Drug Interactions
May increase plasma concentrations with ketoconazole, erythromycin, azithromycin, fluoxetine, and cimetidine.
Lab Interference
May diminish the wheal and flare reactions to skin test antigens.
Action
Description: Desloratadine, the major active metabolite of loratadine, is a non-sedating, long-acting antihistamine. It selectively blocks peripheral histamine H1-receptors.
Onset: Within 1 hour.
Duration: 24 hours.
Pharmacokinetics:
Absorption: Well absorbed. Time to peak plasma concentration: Approx 3 hours.
Distribution: Enters breast milk. Volume of distribution: Approx 49 L/kg. Plasma protein binding: 82-87% (desloratadine); 85-89% (3-hydroxydesloratadine).
Metabolism: Extensively metabolised in the liver into the active metabolite, 3-hydroxydesloratadine, which undergoes further glucuronidation; enzyme(s) responsible for desloratadine metabolism is not yet identified. Decreased metabolism in slow metabolisers of desloratadine.
Excretion: Via urine (41%); faeces (47%). Elimination half-life: Approx 27 hours.
Chemical Structure

Chemical Structure Image
Desloratadine

Source: National Center for Biotechnology Information. PubChem Compound Summary for CID 124087, Desloratadine. https://pubchem.ncbi.nlm.nih.gov/compound/Desloratadine. Accessed May 26, 2022.

Storage
Store between 15-30°C. Storage recommendations may vary among countries or individual products. Refer to specific product guidelines.
MIMS Class
Antihistamines & Antiallergics
ATC Classification
R06AX27 - desloratadine ; Belongs to the class of other antihistamines for systemic use.
References
Aerius Syrup (Organon Malaysia Sdn. Bhd.). National Pharmaceutical Regulatory Agency - Ministry of Health Malaysia. https://www.npra.gov.my. Accessed 25/05/2022.

Aerius Tablets (Organon Malaysia Sdn. Bhd.). National Pharmaceutical Regulatory Agency - Ministry of Health Malaysia. https://www.npra.gov.my. Accessed 25/05/2022.

Ajalorin Orodispersible Tablet 2.5 mg and 5 mg (AJ Research & Pharma Sdn. Bhd.). National Pharmaceutical Regulatory Agency - Ministry of Health Malaysia. https://www.npra.gov.my. Accessed 07/04/2022.

Anon. Desloratadine. AHFS Clinical Drug Information [online]. Bethesda, MD. American Society of Health-System Pharmacists, Inc. https://www.ahfscdi.com. Accessed 25/05/2022.

Anon. Desloratadine. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 07/04/2022.

Avorius 5 mg Tablet (Apex Pharmacy Marketing Sdn Bhd). MIMS Malaysia. http://www.mims.com/malaysia. Accessed 07/04/2022.

Buckingham R (ed). Desloratadine. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 07/04/2022.

Desloratadine 2.5 mg Orodispersible Tablets (Bristol Laboratories Ltd). MHRA. https://products.mhra.gov.uk. Accessed 07/04/2022.

Desloratadine 5 mg Orodispersible Tablets (Bristol Laboratories Ltd). MHRA. https://products.mhra.gov.uk. Accessed 07/04/2022.

Desloratadine Tablet, Film Coated (Lupin Pharmaceuticals, Inc.). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed. Accessed 07/04/2022.

Desloratadine Tablet, Orally Disintegrating (Dr. Reddy’s Laboratories Limited). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed. Accessed 07/04/2022.

Joint Formulary Committee. Desloratadine. British National Formulary [online]. London. BMJ Group and Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 07/04/2022.

Neoclarityn 0.5 mg/mL Oral Solution (Organon Pharma [UK] Limited). MHRA. https://products.mhra.gov.uk. Accessed 07/04/2022.

Neoclarityn 5 mg Film-coated Tablets (Organon Pharma [UK] Limited). MHRA. https://products.mhra.gov.uk. Accessed 07/04/2022.

Disclaimer: This information is independently developed by MIMS based on Desloratadine from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2022 MIMS. All rights reserved. Powered by MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in